CTLA4 and cancer: ICIs amplify T-cell-mediated immune responses against cancer cells by blocking intrinsic immune down-regulators such as anti-cytotoxic T-lymphocyte associated protein 4 (CTLA-4), programmed cell death protein-1 (PD-1), and programmed cell death ligand-1b (PD-L1) (1).